Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will radiation capitalise on its lead over drug-coated stents?

This article was originally published in Clinica

Executive Summary

Drug-coated stents and intravascular brachytherapy products are set to battle it out for market dominance over the next few years. But radiation devices will have the advantage of reaching the market first. That was the clear view of US Bancorp Piper Jaffray analyst Scott Davidson speaking at his company's annual healthcare conference in New York last month. He went on to predict the main developments and controversies expected during the year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT069867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel